The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.
- Read more about Janssen seeks European approval of CAR-T Therapy Ciltacabtagene Autoleucel
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/janssen-seeks-european-approval-of-car-t-therapy-ciltacabtagene-autoleucel
No comments:
Post a Comment